Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.36 |
| ▸ | FABP7 | O15540 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28356620 | 0.86 | SMN1; SMN2 (0.42) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29019459 | 0.86 | SMN1; SMN2 (0.42) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29019435 | 0.86 | SMN1; SMN2 (0.42) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7127095 | 0.80 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL16310478 | 0.78 | KMT2A (0.44) | KMT2AEPHX2PTPN1 | |
| SCHEMBL25362440 | 0.76 | ITGB3 (0.45) | KMT2AEPHX2PTPN1 | |
| SCHEMBL25362437 | 0.76 | ITGB3 (0.45) | KMT2AEPHX2PTPN1 | |
| SCHEMBL7809928 | 0.75 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL1311053 | 0.75 | FABP5 (0.44) | KMT2AFABP5FABP7 | |
| SCHEMBL29823700 | 0.74 | PPARG (0.39) | KMT2AFABP5FABP7EPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660832-B1 | Cyclic peptide compounds with fused benzene rings; solid phase synthesis thereof; use as antibiotic to treat bacterial infection in mammals; may work by binding to RNA targets | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |